Shengtai Pharmaceutical, Inc. to Present at Roth Conference
February 07 2008 - 9:00AM
PR Newswire (US)
WEIFANG, China, Feb. 7 /Xinhua-PRNewswire-FirstCall/ -- Shengtai
Pharmaceutical, Inc. (OTC:SGTI) (BULLETIN BOARD: SGTI) ("Shengtai
Pharmaceutical" or "the Company"), a leading manufacturer and
distributor of high-quality, pharmaceutical grade glucose products
in China, today announced its CFO, Mr. Yizhao Zhang, will present
at the upcoming Roth 20th Annual OC Growth Stock Conference in Dana
Point, California. The date, time and location of Shengtai
Pharmaceutical, Inc.'s presentation at the conference are as
follows: Date: Thursday, February 21, 2008 Time: 10:30 a.m. Pacific
Time Venue: Ritz Ballroom Salon 1 The Ritz Carlton Laguna Niguel
One Ritz-Carlton Drive Dana Point, California 92629 Webcast:
http://www.wsw.com/webcast/roth16/sgti/ A replay of the call will
be available for 90 days following the presentation using the same
link and will also be available on the Company's website. The ROTH
20th Annual OC Conference will feature presentations from over 300
small-cap companies including over 40 U.S.-listed Chinese
companies. The distinguished list of presenting companies have been
identified by Roth Capital's award-winning research team and are
representative of a broad spectrum of sectors, including
Technology, Healthcare, Energy and Industrial as well as Consumer
Products. Interested parties and investors may find more
information for the conference by visiting the website at
http://www.rothcapital.com/. About Shengtai Pharmaceutical, Inc.
Shengtai Pharmaceutical, Inc. through its wholly-owned subsidiary
Shengtai Holding, Inc. (SHI), a New Jersey corporation, and the
holding company for Weifang Shengtai Pharmaceutical Co., Ltd., is a
leading manufacturer and supplier of glucose products, which
include pharmaceutical grade glucose used for medical purposes, and
glucose and cornstarch products for the food and beverage industry
and for industrial production in China. For more information about
Shengtai Pharmaceutical, Inc. please visit
http://www.shengtaipharmaceutical.com/. Safe Harbor Statement Safe
Harbor Statement Under the Private Securities Litigation Reform Act
of 1995: Certain statements in this press release and oral
statements made by the Company, constitute forward-looking
statements for purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995. These statements
include, without limitation, statements regarding our ability to
prepare the company for growth, the Company's planned capacity
expansion in 2008 and predictions and guidance relating to the
Company's future financial performance. We have based these
forward-looking statements largely on our current expectations and
projections about future events and financial trends that we
believe may affect our financial condition, results of operations,
business strategy and financial needs but they involve risks and
uncertainties that could cause actual results to differ materially
from those in the forward-looking statements, which may include,
but are not limited to, such factors as unanticipated changes in
product demand especially in the pharmaceutical industry, pricing
and demand trends for the Company's products, changes to government
regulations, risk associated with operation of the Company's new
facilities, risk associated with large scale implementation of the
company's business plan, the ability to attract new customers,
ability to increase its product's applications, cost of raw
materials, downturns in the Chinese economy, and other information
detailed from time to time in the Company's filings and future
filings with the United States Securities and Exchange Commission.
Investors are urged to consider these factors carefully in
evaluating the forward-looking statements herein and are cautioned
not to place undue reliance on such forward-looking statements,
which are qualified in their entirety by this cautionary statement.
The forward-looking statements made herein speak only as of the
date of this press release and the Company undertakes no duty to
update any forward-looking statement to conform the statement to
actual results or changes in the company's expectations.
DATASOURCE: Shengtai Pharmaceutical, Inc. CONTACT: Mr. Yizhao
Zhang, CFO of Shengtai Pharmaceutical, Inc., +86-536-629-5728, ; or
Investor Relations Contact, Mr. Crocker Coulson, President of CCG
Elite Investor Relations, +1-646-213-1915, NY Office, Web site:
http://www.shengtaipharmaceutical.com/ http://www.rothcapital.com/
http://www.wsw.com/webcast/roth16/sgti
Copyright